Skip to main content

Advertisement

SpringerLink
Log in

Vasculitis

Mepolizumab for eosinophilic granulomatosis with polyangiitis

  • News & Views
  • Published:

From Nature Reviews Rheumatology

View current issue Sign up to alerts

Targeting IL-5 could improve outcomes and have steroid-sparing effects in the management of eosinophilic granulomatosis with polyangiitis. However, some questions remain about how this approach affects specific aspects of the disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Comarmond, C. et al. Eosinophilic granulomatosis with polyangiitis (Churg Strauss). Clinical characteristics and long term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. Arthritis Rheum. 65, 270–281 (2013).

    Article  Google Scholar 

  2. Sarnes, E. et al. Incidence and US costs of corticosteroid-associated adverse events: a systematic literature review. Clin. Ther. 33, 1413–1432 (2011).

    Article  Google Scholar 

  3. Khoury, P., Grayson, P. C. & Klion, A. D. Eosinophils in vasculitis: characteristics and roles in pathogenesis. Nat. Rev. Rheumatol. 10, 474–483 (2014).

    Article  CAS  Google Scholar 

  4. Jakiela, B. et al. Increased production of IL-5 and dominant Th2-type response in airways of Churg–Strauss syndrome patients. Rheumatology (Oxford) 51, 1887–1893 (2012).

    Article  CAS  Google Scholar 

  5. Ortega, H. G. et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N. Engl. J. Med. 371, 1198–1207 (2014).

    Article  Google Scholar 

  6. Wechsler, M. E. et al. Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N. Engl. J. Med. 376, 1921–1932 (2017).

    Article  CAS  Google Scholar 

  7. Groh, M. et al. Eosinophilic granulomatosis with polyangiitis (Churg–Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. Eur. J. Intern. Med. 26, 545–553 (2015).

    Article  Google Scholar 

  8. Sablé-Fourtassou, R. et al. Antineutrophil cytoplasmic antibodies and the Churg–Strauss syndrome. Ann. Intern. Med. 143, 632–638 (2005).

    Article  Google Scholar 

  9. Smith, K. Genetic studies in ANCA-associated vasculitis point to a new, practical disease classification based on autoantibody specificity. Presented at the 18th International Vasculitis and ANCA Workshop, Tokyo, Japan. Rheumatology (Oxford) 56 (Suppl. S3), iii3 (2017).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Loïc Guillevin is at the French Vasculitis Study Group, Referral Center for Rare Systemic and Autoimmune Diseases: Vasculitis and Scleroderma, Hôpital Cochin, APHP, Université Paris Descartes, Paris, France.,

    Loïc Guillevin

Authors
  1. Loïc Guillevin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Loïc Guillevin.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Guillevin, L. Mepolizumab for eosinophilic granulomatosis with polyangiitis. Nat Rev Rheumatol 13, 518–519 (2017). https://doi.org/10.1038/nrrheum.2017.117

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrrheum.2017.117

  • Springer Nature Limited

This article is cited by

Search

Navigation